A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT07015242
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Specified dose on specified days
  • Methotrexate — DRUG
    Specified dose on specified days
  • Procarbazine — DRUG
    Specified dose on specified days
  • Temozolomide — DRUG
    Specified dose on specified days
  • Liso-cel — BIOLOGICAL
    Specified dose on specified days
  • Fludarabine — DRUG
    Specified dose on specified days
  • Cyclophosphamide — DRUG
    Specified dose on specified days
  • Calcium folinate — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Key Dates

Start date
Nov 6, 2025
Status verified
Jun 2026
Primary completion
Jan 9, 2028
Completion
Dec 10, 2028

Study Design

Enrollment
65 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liso-cel Administration

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: 12 months after liso-cel infusion ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (14)

FacilityCityStateZIPSite coordinators
University Of ColoradoAuroraColorado80045
Bradley Haverkos, Site 0305
513-543-8460
Moffitt Cancer CenterTampaFlorida33612-9416
Supreet Kaur, Site 0308
Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicagoIllinois60611
Reem Karmali, Site 0311
312-695-0990
Dana-Farber Cancer InstituteBostonMassachusetts02215
Lakshmi Nayak, Site 0313
617-632-2166
Washington University School of Medicine in St. LouisSt LouisMissouri63110-1010
Armin Ghobadi, Site 0316
314-454-8323
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08901
Matt Matasar, Site 0315
405-713-4950
Roswell Park Comprehensive Cancer CenterBuffaloNew York14263
Grant Schofield, Site 0310
Memorial Sloan Kettering Cancer CenterNew YorkNew York10021
Michael Scordo, Site 0301
646-608-4132
Cleveland ClinicClevelandOhio44195
Allison Winter, Site 0302
216-445-4782
The Ohio State University Comprehensive Cancer CenterColumbusOhio43202-2224
Nathan Denlinger, Site 0309
University of PennsylvaniaPhiladelphiaPennsylvania19104
Sunita Nasta, Site 0304
215-662-6933
Sarah Cannon Research Institute Oncology PartnersNashvilleTennessee37203
Krish Patel, Site 0312
206-215-2338
MD Anderson Cancer CenterHoustonTexas77030
Ayushi Chauhan, Site 0303
Fred Hutchinson Cancer CenterSeattleWashington98109
Vyshak Alva Venur, Site 0306

Find similar trials in Aurora, CO

By research site
University Of Colorado· Aurora, COMoffitt Cancer Center· Tampa, FLRobert H. Lurie Comprehensive Cancer Center of Northwestern University· Chicago, ILDana-Farber Cancer Institute· Boston, MAWashington University School of Medicine in St. Louis· St Louis, MORutgers Cancer Institute of New Jersey· New Brunswick, NJ

Related Studies